Case report: Successful use of mepolizumab for immune checkpoint inhibitors–induced hypereosinophilic syndrome in two patients with solid malignancies

Case report: Successful use of mepolizumab for immune checkpoint inhibitors–induced hypereosinophilic syndrome in two patients with solid malignancies

Hypereosinophilic syndrome (HES) represents a group of blood disorders characterized by an absolute eosinophil count (AEC) > 1.5 × 103/μl in the peripheral blood, which eventually extravasate and cause organ damage. It can be primary or secondary to infections or tumors. The infiltration of e...

Full description

Bibliographic Details
Main Authors: Chiara Lazzari, Mona Rita Yacoub, Corrado Campochiaro, Alessandra Bulotta, Diego Palumbo, Francesca Rita Ogliari, Lorenzo Dagna, Silvia Marchesi, Maurilio Ponzoni, Vanesa Gregorc
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
HES
NSCLC
mepolizumab
immune checkpoint inhibitor
mesothelioma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1079034/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1079034/full

Similar Items